Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Do analysts rate GMAB or TAK?

Genmab A/S currently has a consensus price target of $39.25, indicating a potential upside of 40.57%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Takeda Pharmaceutical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media favor GMAB or TAK?

In the previous week, Takeda Pharmaceutical had 5 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for Takeda Pharmaceutical and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.29 beat Takeda Pharmaceutical's score of 0.53 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, GMAB or TAK?

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

Which has stronger valuation & earnings, GMAB or TAK?

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	5.74	$1.14B	$1.99	14.03
Takeda Pharmaceutical	$30.09B	1.59	$712.33M	$0.30	50.22

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 37.53% compared to Takeda Pharmaceutical's net margin of 3.20%. Genmab A/S's return on equity of 21.03% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Takeda Pharmaceutical	3.20%	10.50%	5.10%

Summary

Genmab A/S beats Takeda Pharmaceutical on 13 of the 17 factors compared between the two stocks.